Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition...

Róbert Wessman to continue serving as Executive Chairman in full-time capacityLisa Graver appointed Chief Executive Officer REYKJAVIK, ICELAND (January 6, 2026) — Alvotech (NASDAQ: ALVO), a global...

USD 100 million senior term loan facility with a 2-year maturityStrengthens liquidity to support execution across Alvotech’s R&D pipeline and global product launches through 2026Led by GoldenTree...

Attached is a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding changes in company's own shares. Attachment Alvotech Own Shares...

Alvotech (NASDAQ: ALVO, ALVO SDB) today publishes its financial calendar for 2026. Annual or interim results are released on the dates specified below, after the close of U.S. markets. An investor...

Introduction of AVT05 supported by NHS England tender award in the United Kingdom REYKJAVIK, ICELAND (December 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the...

According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain...

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH...

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH...

REYKJAVIK, ICELAND (November 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today...